HENAN SUNLAKE ENTERPRISE CORPORATION
Free supplier Enterprise Certification
- Free
supplier - 9th
years
Free supplier Enterprise Certification
Product Certification&
Enterprise Certification
Country: 
China (Mainland)
Business Type:Trading Company
Tel: +86-371- 86259723
Tel: 17734809689
Tel: 17734809689
Tel: 86-371-86259723
Tel: 17734809689
Tel: 17734809689
Mobile: 17734809689
Tel: +86-371- 86259723
Fax: +86-371- 86259723
Province/state: HENAN
City: ZHENGZHOU
Street: Mingmen International Center, NO.222 Dongming Road,Zhengzhou,Henan,China
MaxCard:
Contact Suppliers
CAS NO.50-78-2
Our Services
1.Certificate Of Analysis (COA)
2.Material Safety Data Sheet (MSDS)
3.Route of synthesis (ROS)
4.Method of Aanlysis (MOA)
5.Nuclear Magnetic Resonance (NMR)
6.Packing pictures and loading video before loading
7.Free Sample
9.Factory audit
10.Strong after-sale service
Company information
Henan Sunlake Enterprise Corporation is located in Henan Province , The central plain of China , Which enjoys favorable geogeaphical position and convenient transportion, The com[any was established in june. 1998 , until now having more than 18 years experience in manufacturing & exporting chemical raw material .Sunlake is a professional manufacturer engaged in producing and selling chemicals,including Organic & inorganic chemicals , pigments & Dyestuffs , Water treatment chemicals , Food & FEED additives and others . these products have been being well exported to europe , southeast Asia , the Middle East , Africa , South America and some other countries and areas.We sincerely welcome foreign friends to visit our plant for cooperation. With the idea of "quality first,credit priority, Excellent service", We are highly acknowledged by customers for good quality and competitive price. More importantly , the company has a strong R & D team, who are professional engineers and scholars with Ph. D. .So we are confident to serve you better with our high - quality products and professional team.We are taking great efforts to provide our customers with demanded goods and professional services, and continuously improve our core ability of competition and get the momentum for sustainable development, and finally make us being a reliable and professional wupplier in international market.We welcome any serious inquiries from all customers of the world, and sincerely hope to cooperate.
| C9H8O4 |
| Acetylsalicylic acid Basic information |
| Product Name: | Acetylsalicylic acid |
| Synonyms: | O-ACETYLSALICYLIC ACID;O-ACETOXYBENZOIC ACID;ACETICYL;ACETOXYBENZOIC ACID;ACETYLSALICYLIC ACID;ACETYSALICYLIC ACID;ACETYLSALICYLIC ACID IMPURITY D;ALKENYL SUCCINIC ANHYDRIDES |
| CAS: | 50-78-2 |
| MF: | C9H8O4 |
| MW: | 180.16 |
| EINECS: | 200-064-1 |
| Product Categories: | Pharmaceutical;Aromatics Compounds;Aromatics;Intermediates & Fine Chemicals;Pharmaceuticals;Lipid signaling;Anti-Allergic Agents, Antibiotic;Isotope;LOPROX |
| Mol File: | 50-78-2.mol |
|
|
|
| Acetylsalicylic acid Chemical Properties |
| mp | 134-136 °C(lit.) |
| density | 1.35 |
| Fp | 250 °C |
| storage temp. | Store at RT. |
| solubility | H2O: 10 mg/mL at 37 °C |
| form | crystalline |
| color | white |
| Water Solubility | 3.3 g/L (20 ºC) |
| Merck | 14,851 |
| BRN | 779271 |
| Stability: | Stable. Keep dry. Incompatible with strong oxidizing agents, strong bases, strong acids, various other compounds such as iodides, iron salts, quinine salts, etc. |
| CAS DataBase Reference | 50-78-2(CAS DataBase Reference) |
| NIST Chemistry Reference | Benzoic acid, 2-(acetyloxy)-(50-78-2) |
| EPA Substance Registry System | Benzoic acid, 2-(acetyloxy)-(50-78-2) |
| Safety Information |
| Hazard Codes | Xn |
| Risk Statements | 22-36/37/38 |
| Safety Statements | 26-36/37/39 |
| RIDADR | UN 1851 |
| WGK Germany | 1 |
| RTECS | VO0700000 |
| PackingGroup | III |
| Hazardous Substances Data | 50-78-2(Hazardous Substances Data) |
| MSDS Information |
| Provider | Language |
|---|---|
| Acetylsalicylic acid | English |
| ACROS | English |
| SigmaAldrich | English |
| ALFA | English |
| Acetylsalicylic acid Usage And Synthesis |
| What’s acetylsalicylic acid |
Acetylsalicylic acid, also known as aspirin, is an analgesic-antipyretic medicine made by salicylic acid interacting with acetic anhydride. It is a white crystalline powder, odorless, stable in dry air. It will be slowly hydrolyzed to be salicylic acid and acetic acid in moist air, and aqueous solution has acidic reaction. Slightly soluble in water, soluble in ethanol, ethyl ether, chloroform, sodium hydroxide solution and sodium carbonate solution. Acetylsalicylic acid has antipyretic analgesic, anti-inflammatory and anti-rheumatism effect, that’s why it is often used for fever, headache, muscle pain, neuralgia, rheumatic fever, acute rheumatic arthritis, gout, etc.; also it has antiplatelet aggregation effect, and can be used for prevention of arterial thrombosis, atherosclerosis, transient cerebral ischemia and myocardial infarction; in addition, acetylsalicylic acid also can be used in the treatment of biliary tract roundworm disease and athlete's foot. 【Pharmacological actions】Acetylsalicylic acid is one of the traditional antipyretic analgesics, as well as the role of platelet aggregation. Acetylsalicylic acid in the body has the characteristics of the antithrombotic, can reduce the formation of obstructive blood clots in surrounding arteries, and inhibit release of platelet response and endogenous ADP, 5 - HT, etc., therefore to inhibit second phase other than the first phase of platelet aggregation. The mechanism of action of acetylsalicylic acid is to make platelets cyclooxygenase acetylation, thus inhibiting the formation of ring peroxide, and TXA2 formation is also reduced as well. At the mean time make the platelet membrane protein acetylation, and inhibit platelet membrane enzyme, which helps to inhibit platelet function. As the cyclooxygenase is inhibited, it impacts blood vessel wall synthesized to be PGI2, the platelet TXA2 synthetic enzymes also to be inhibited; so it would impact formation of both TXA2 and PGI2 when it is large doses. Suitable for ischemic heart disease, after percutaneous transluminal coronary angioplasty or c |